Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Onkure Therapeutics, Inc. (OKUR) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Onkure Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1637715.
Total stock buying since 2021: $33,389,003.
Total stock sales since 2021: $5,182,360.
Total stock option exercises since 2021: $346,744.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 1,400,000 | $2,590,000 | 1,842,126 | $3,424,842 | 0 | $0 |
| 2024 | 1,199,482 | $1,728,044 | 0 | $0 | 0 | $0 |
| 2023 | 125,000 | $1,000,000 | 115,625 | $807,762 | 15,625 | $28,125 |
| 2022 | 14,755 | $48,675 | 0 | $0 | 50,000 | $98,500 |
| 2021 | 1,964,563 | $28,022,284 | 111,736 | $949,756 | 111,736 | $220,119 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-06 | 0 | $0 | 391 | $931 | 0 | $0 |
| 2025-05 | 1,400,000 | $2,590,000 | 1,837,739 | $3,412,164 | 0 | $0 |
| 2025-04 | 0 | $0 | 3,996 | $11,747 | 0 | $0 |
| 2024-09 | 513,375 | $705,246 | 0 | $0 | 0 | $0 |
| 2024-08 | 271,826 | $380,663 | 0 | $0 | 0 | $0 |
| 2024-05 | 414,281 | $642,135 | 0 | $0 | 0 | $0 |
| 2023-08 | 0 | $0 | 15,625 | $98,062 | 15,625 | $28,125 |
| 2023-06 | 0 | $0 | 100,000 | $709,700 | 0 | $0 |
| 2023-05 | 125,000 | $1,000,000 | 0 | $0 | 0 | $0 |
| 2022-09 | 7,500 | $25,447 | 0 | $0 | 0 | $0 |
| 2022-08 | 7,255 | $23,228 | 0 | $0 | 50,000 | $98,500 |
| 2021-08 | 15,500 | $119,790 | 0 | $0 | 0 | $0 |
| 2021-07 | 111,736 | $949,756 | 111,736 | $949,756 | 111,736 | $220,119 |
| 2021-06 | 96,946 | $886,763 | 0 | $0 | 0 | $0 |
| 2021-05 | 7,049 | $65,995 | 0 | $0 | 0 | $0 |
| 2021-04 | 1,733,332 | $25,999,980 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-23 | Leverone Jason A. (Chief Financial Officer) | Sale | 303 | 2.38 | 722 |
| 2025-06-23 | Saccomano Nicholas A (President and CEO) | Sale | 88 | 2.38 | 209 |
| 2025-05-15 | Chen Bihua | Sale | 1,813,439 | 1.85 | 3,363,929 |
| 2025-05-15 | Hove Anders D | Buy | 1,400,000 | 1.85 | 2,590,000 |
| 2025-05-12 | Chen Bihua | Sale | 24,300 | 1.99 | 48,235 |
| 2025-04-07 | Leverone Jason A. (Chief Financial Officer) | Sale | 1,844 | 2.67 | 4,925 |
| 2025-04-07 | Saccomano Nicholas A (President and CEO) | Sale | 516 | 2.67 | 1,378 |
| 2025-04-04 | Leverone Jason A. (Chief Financial Officer) | Sale | 1,278 | 3.33 | 4,253 |
| 2025-04-04 | Saccomano Nicholas A (President and CEO) | Sale | 358 | 3.33 | 1,191 |
| 2024-09-25 | Leonard Braden Michael | Buy | 68,746 | 1.50 | 102,844 |
| 2024-09-24 | Leonard Braden Michael | Buy | 29,600 | 1.41 | 41,854 |
| 2024-09-18 | Leonard Braden Michael | Buy | 806 | 1.40 | 1,128 |
| 2024-09-17 | Leonard Braden Michael | Buy | 55,300 | 1.36 | 75,097 |
| 2024-09-16 | Leonard Braden Michael | Buy | 172,747 | 1.37 | 236,836 |
| 2024-09-13 | Leonard Braden Michael | Buy | 150,000 | 1.31 | 196,950 |
| 2024-09-12 | Leonard Braden Michael | Buy | 36,176 | 1.40 | 50,537 |
| 2024-08-14 | Leonard Braden Michael | Buy | 100,487 | 1.41 | 141,988 |
| 2024-08-13 | Leonard Braden Michael | Buy | 171,339 | 1.39 | 238,675 |
| 2024-05-14 | Leonard Braden Michael | Buy | 414,281 | 1.55 | 642,135 |
| 2023-08-28 | Hall Ashley (Chief Development Officer) | Sale | 15,625 | 6.28 | 98,062 |
| 2023-08-28 | Hall Ashley (Chief Development Officer) | Option Ex | 15,625 | 1.80 | 28,125 |
| 2023-06-23 | Novo Holdings A/s (10% Owner) | Sale | 100,000 | 7.10 | 709,700 |
| 2023-05-08 | O'donnell Niall (Director) | Buy | 125,000 | 8.00 | 1,000,000 |
| 2022-09-01 | Cruse Michael (Chief Operating Officer) | Buy | 7,500 | 3.39 | 25,447 |
| 2022-08-31 | Cruse Michael (Chief Operating Officer) | Buy | 3,212 | 3.21 | 10,307 |
| 2022-08-31 | Grey Michael G (Executive Chairman) | Option Ex | 50,000 | 1.97 | 98,500 |
| 2022-08-30 | Cruse Michael (Chief Operating Officer) | Buy | 2,820 | 3.18 | 8,959 |
| 2022-08-29 | Cruse Michael (Chief Operating Officer) | Buy | 1,223 | 3.24 | 3,962 |
| 2021-08-25 | Jindal Vineet R. (Chief Financial Officer) | Buy | 5,000 | 7.43 | 37,175 |
| 2021-08-25 | Cruse Michael (Senior VP-Corporate Operations) | Buy | 2,500 | 7.45 | 18,615 |
| 2021-08-25 | Flesher Gregory J. (President and CEO) | Buy | 8,000 | 8.00 | 64,000 |
| 2021-07-14 | Muralidhar Bali (Director) | Buy | 111,736 | 8.50 | 949,756 |
| 2021-07-14 | Johnson Wendy S. (Chief Development Officer) | Sale | 111,736 | 8.50 | 949,756 |
| 2021-07-08 | Johnson Wendy S. (Chief Development Officer) | Option Ex | 111,736 | 1.97 | 220,119 |
| 2021-06-23 | Muralidhar Bali | Buy | 20,710 | 9.28 | 192,250 |
| 2021-06-22 | Muralidhar Bali | Buy | 14,615 | 8.72 | 127,486 |
| 2021-06-21 | Muralidhar Bali | Buy | 32,659 | 9.03 | 294,943 |
| 2021-06-08 | Muralidhar Bali | Buy | 16,605 | 9.50 | 157,714 |
| 2021-06-04 | Muralidhar Bali | Buy | 257 | 9.42 | 2,421 |
| 2021-06-03 | Muralidhar Bali | Buy | 12,100 | 9.25 | 111,949 |
| 2021-05-28 | Muralidhar Bali | Buy | 14 | 9.50 | 133 |
| 2021-05-27 | Muralidhar Bali | Buy | 1,120 | 9.26 | 10,368 |
| 2021-05-26 | Muralidhar Bali | Buy | 5,915 | 9.38 | 55,494 |
| 2021-04-13 | O'donnell Niall (Director) | Buy | 200,000 | 15.00 | 3,000,000 |
| 2021-04-13 | Sonsini Peter W. (10% Owner) | Buy | 666,666 | 15.00 | 9,999,990 |
| 2021-04-13 | Novo Holdings A/s (10% Owner) | Buy | 666,666 | 15.00 | 9,999,990 |
| 2021-04-09 | Rivervest Venture Fund Iv, L.p. (10% Owner) | Buy | 200,000 | 15.00 | 3,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of OKUR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Onkure Therapeutics, Inc. (symbol OKUR, CIK number 1637715) see the Securities and Exchange Commission (SEC) website.